Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Feb 1.

Published in final edited form as: J Immunother. 2013 Feb;36(2):152–157. doi: 10.1097/CJI.0b013e3182811ae4

Table 2.

Lymphocyte Subset Changes Following DC Vaccination

	ATL-DC Trial	GAA-DC Trial
Lymphocyte Subset^*	Post-Tx (Avg %)	Post-Tx (Avg %)
CD3⁺CD4⁺ Helper T cells	37+/-3.0	43.1+/-4.4
CD3⁺CD8⁺ CTL	23.5+/-2.5	27.7+/-4.5
CD3⁺CD16⁺ NK T cells	2.6+/-0.9	4.7+/-1.8
CD3^-CD16⁺ NK cells	15.6+/-1.5	13.22+/-3.7
CD3^-CD16⁺CD25⁺ activ. NK	9.1+/-2.5	39.5+/-5.9
CD3^-CD19⁺ B cells	10.2+/-1.6	9.5+/-0.6
CD3⁺CD4⁺CD25⁺CD127^low Treg	17.1+/-3.1	23.3+/-3.9

^*

Percent of cells stained from ficoll-isolated PBMC at each timepoint.